13F reference period
Q2 2026
Security Snapshot
ESPERION THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (ESPR) Institutional Ownership
CUSIP: 29664W105
13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026
Institutions Reporting
191
Shares (Excl. Options)
205.19M
Full value: 205,187,468 · shares · 30 Jun 2026Price
$3.16
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- ESPR
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 205,187,468
- Total 13F value
- $646,775,990
- Portfolio coverage rank
- 0.01%
- Share change
- +30,386,931
- Value change
- +$118,634,012
- Number of holders
- 191
- Shares outstanding
- 257,047,105
- SEC-reported price per share
- $3.19
- Insider filing price
- $3.19
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- ESPR - ESPERION THERAPEUTICS, INC. - Common Stock, par value $0.001 per share is tracked under CUSIP 29664W105.
- 191 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 206 to 191 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$479.24M
Full value: $479,240,065 · USD · 31 Mar 2026.$646.78M
Full value: $646,775,990 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 191 institutions filings for Q2 2026.
Security key
29664W105
13F reference period
Q2 2026
13F holders
191
13D/G owners
6
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29664W105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
ESPR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GLAZER CAPITAL, LLC | 8.2% | $65,443,934 | 20,975,620 | Glazer Capital, LLC | 01 Jun 2026 | |||
| GOLDMAN SACHS GROUP INC | 6.7% | $54,938,678 | 17,222,156 | THE GOLDMAN SACHS GROUP, INC. | 30 Jun 2026 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1% | $41,805,282 | 13,105,104 | Vanguard Capital Management | 30 Jun 2026 | |||
| Two Seas Capital LP | 4.7% | -6% | $25,836,769 | -$543,915 | 9,749,724 | -2.1% | Two Seas Capital LP | 30 Sep 2025 |
| BB BIOTECH AG | 4.9% | -2% | $8,821,598 | -$227,500 | 9,694,064 | -2.5% | BB Biotech AG | 04 Mar 2025 |
| WASATCH ADVISORS LP | 0.7% | -90% | $6,094,173 | -$43,692,965 | 1,930,185 | -88% | Wasatch Advisors LP | 30 Jun 2026 |
As of 30 Jun 2026,
191
institutional investors reported holding
shares of
ESPERION THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (ESPR).
This represents
80%
of the company’s total
outstanding shares.
205.19M
Full value: 205,187,468 · shares · 30 Jun 2026257.05M
Full value: 257,047,105 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
61%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| GLAZER CAPITAL, LLC | 8.7% | 22,416,339 | 1.7% | $70,836,000 | |
| BlackRock, Inc. | 8.6% | 22,128,021 | +24% | 0% | $69,924,547 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.4% | 11,427,437 | +9.5% | 0% | $36,110,701 |
| Trium Capital LLP | 4.3% | 11,158,150 | 22% | $35,259,754 | |
| GOLDMAN SACHS GROUP INC | 4% | 10,380,646 | +331% | 0% | $32,802,842 |
| STATE STREET CORP | 2.8% | 7,276,249 | +3.1% | 0% | $22,992,947 |
| TWO SIGMA INVESTMENTS, LP | 2.8% | 7,126,739 | -25% | 0.02% | $22,520,495 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.6% | 6,629,966 | +11% | 0% | $20,955,448 |
| AQR Arbitrage LLC | 2.4% | 6,046,463 | 0.27% | $19,106,823 | |
| ODDO BHF ASSET MANAGEMENT SAS | 1.9% | 5,000,000 | 0.74% | $15,800,000 | |
| Balyasny Asset Management L.P. | 1.8% | 4,654,778 | 0.03% | $14,709,098 | |
| FMR LLC | 1.8% | 4,612,705 | +1132% | 0% | $14,576,148 |
| Beryl Capital Management LLC | 1.7% | 4,431,598 | 13% | $14,003,850 | |
| PenderFund Capital Management Ltd. | 1.5% | 3,884,508 | -0.19% | 1.6% | $12,275,045 |
| UBS Group AG | 1.5% | 3,836,202 | -11% | 0% | $12,122,398 |
| ALLIANCEBERNSTEIN L.P. | 1.4% | 3,587,702 | +1271% | 0% | $9,830,303 |
| PSquared Asset Management AG | 1.3% | 3,300,000 | 3.4% | $10,428,000 | |
| NEXPOINT ASSET MANAGEMENT, L.P. | 1.1% | 2,955,920 | 0.62% | $9,340,708 | |
| GABELLI FUNDS LLC | 1.1% | 2,878,952 | 0.06% | $9,097,488 | |
| TIG Advisors, LLC | 1% | 2,587,840 | 0.38% | $8,177,574 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.96% | 2,471,671 | -30% | 0% | $7,810,480 |
| NORTHERN TRUST CORP | 0.9% | 2,321,824 | +10% | 0% | $7,336,964 |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 0.9% | 2,315,900 | 1.1% | $7,318,244 | |
| MILLENNIUM MANAGEMENT LLC | 0.87% | 2,225,733 | +268% | 0% | $7,033,316 |
| Sagefield Capital LP | 0.85% | 2,190,108 | 0.51% | $6,920,742 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
51
Headline period
Q2 2026
Rows shown
1-25 of 51
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 0 | $0 | -$52,818,284 | $3.19 | 0 |
| 2026 Q2 | 205,187,468 | $646,775,990 | +$118,634,012 | $3.16 | 191 |
| 2026 Q1 | 174,839,194 | $479,240,065 | +$58,157,398 | $2.74 | 206 |
| 2025 Q4 | 151,305,588 | $559,772,067 | +$165,257,335 | $3.70 | 201 |
| 2025 Q3 | 107,960,329 | $286,090,424 | +$31,947,033 | $2.65 | 187 |
| 2025 Q2 | 98,221,986 | $96,659,560 | -$21,194,525 | $0.98 | 161 |
| 2025 Q1 | 111,244,473 | $160,207,390 | -$24,300,645 | $1.44 | 183 |
| 2024 Q4 | 126,046,299 | $277,285,420 | +$4,393,183 | $2.20 | 188 |
| 2024 Q3 | 128,986,677 | $212,839,069 | -$18,982,245 | $1.65 | 181 |
| 2024 Q2 | 136,753,565 | $303,582,298 | +$17,706,459 | $2.22 | 173 |
| 2024 Q1 | 125,253,343 | $335,669,495 | +$141,351,114 | $2.68 | 147 |
| 2023 Q4 | 71,634,221 | $214,185,830 | -$13,154,422 | $2.99 | 127 |
| 2023 Q3 | 77,232,361 | $75,678,982 | -$1,733,880 | $0.98 | 120 |
| 2023 Q2 | 74,286,796 | $103,280,736 | -$10,483,186 | $1.39 | 121 |
| 2023 Q1 | 80,929,285 | $128,750,548 | -$22,081,506 | $1.59 | 161 |
| 2022 Q4 | 73,478,005 | $457,748,937 | +$39,215,603 | $6.23 | 164 |
| 2022 Q3 | 62,444,882 | $418,381,560 | +$53,328,619 | $6.70 | 143 |
| 2022 Q2 | 55,366,705 | $352,132,262 | +$24,287,037 | $6.36 | 128 |
| 2022 Q1 | 51,922,058 | $241,219,302 | -$10,656,706 | $4.64 | 121 |
| 2021 Q4 | 53,613,124 | $268,022,905 | +$97,310,967 | $5.00 | 119 |
| 2021 Q3 | 24,797,305 | $298,815,522 | -$61,530,602 | $12.05 | 133 |
| 2021 Q2 | 28,340,478 | $599,385,890 | -$18,947,335 | $21.15 | 140 |
| 2021 Q1 | 28,702,213 | $805,059,737 | -$64,474,348 | $28.05 | 151 |
| 2020 Q4 | 30,878,165 | $802,895,778 | -$34,208,444 | $26.00 | 152 |
| 2020 Q3 | 31,640,175 | $1,176,015,102 | -$28,756,691 | $37.17 | 165 |